Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma

被引：0
|
作者：
You-Liang Lai
Kai-Hung Wang
Hsing-Pang Hsieh
Wan-Ching Yen
机构：
[1] National Health Research Institutes,Institute of Biotechnology and Pharmaceutical Research
[2] Buddhist Tzu Chi Medical Foundation,Department of Medical Research, Hualien Tzu Chi Hospital
来源：
Journal of Biomedical Science | / 29卷
关键词：
Hepatocellular carcinoma; Multikinase inhibitors; Aurora kinases; Sorafenib resistance;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma
    Lai, You-Liang
    Wang, Kai-Hung
    Hsieh, Hsing-Pang
    Yen, Wan-Ching
    JOURNAL OF BIOMEDICAL SCIENCE, 2022, 29 (01)
  • [2] Adjutant therapeutic strategy for sorafenib-resistant hepatocellular carcinoma
    Peng, Syue-Wei
    Lin, Yi-Heng
    Teng, Ming-Hao
    Lai, Hung-Cheng
    Chang, Te-Sheng
    Huang, Yen-Hua
    CANCER RESEARCH, 2018, 78 (13)
  • [3] Metabolic implication of tigecycline as an efficacious second-line treatment for sorafenib-resistant hepatocellular carcinoma
    Messner, Martina
    Schmitt, Sabine
    Ardelt, Maximilian A.
    Froehlich, Thomas
    Mueller, Martin
    Pein, Helmut
    Huber-Cantonati, Petra
    Ortler, Carina
    Koenig, Lars M.
    Zobel, Lena
    Koeberle, Andreas
    Arnold, Georg J.
    Rothenfusser, Simon
    Kiemer, Alexandra K.
    Gerbes, Alexander L.
    Zischka, Hans
    Vollmar, Angelika M.
    Pachmayr, Johanna
    FASEB JOURNAL, 2020, 34 (09): : 11860 - 11882
  • [4] Fucoidan inhibits EGFR redistribution and potentiates sorafenib to overcome sorafenib-resistant hepatocellular carcinoma
    Luo, Jialiang
    Li, Lei
    Zhu, Zhengyumeng
    Chang, Bo
    Deng, Fan
    Wang, Di
    Lu, Xiao
    Zuo, Daming
    Chen, Qingyun
    Zhou, Jia
    BIOMEDICINE & PHARMACOTHERAPY, 2022, 154
  • [5] Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells
    Shi, Tingting
    Iwama, Hisakazu
    Fujita, Koji
    Kobara, Hideki
    Nishiyama, Noriko
    Fujihara, Shintaro
    Goda, Yasuhiro
    Yoneyama, Hirohito
    Morishita, Asahiro
    Tani, Joji
    Yamada, Mari
    Nakahara, Mai
    Takuma, Kei
    Masaki, Tsutomu
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (23)
  • [6] High FLT3 Levels May Predict Sorafenib Benefit in Hepatocellular Carcinoma
    Sun, Wen
    Li, Shi-Chao
    Xu, Li
    Zhong, Wei
    Wang, Zhen-Guang
    Pan, Chu-Zhi
    Li, Jing
    Jin, Guang-Zhi
    Ta, Na
    Dong, Wei
    Liu, Dan
    Liu, Hui
    Wang, Hong-Yang
    Ding, Jin
    CLINICAL CANCER RESEARCH, 2020, 26 (16) : 4302 - 4312
  • [7] A novel strategy for sorafenib-resistant hepatocellular carcinoma: autotaxin Inhibition by PF-8380
    Kwak, Bong Jun
    Park, Jung Hyun
    Kim, Ok-Hee
    Lee, Dosang
    Hong, Tae Ho
    Lee, Sang Chul
    Kim, Kee-Hwan
    Choi, Ho Joong
    Kim, Say-June
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2025, 151 (03)
  • [8] Transcriptomics-Based Drug Repurposing Approach Identifies Novel Drugs against Sorafenib-Resistant Hepatocellular Carcinoma
    Regan-Fendt, Kelly
    Li, Ding
    Reyes, Ryan
    Yu, Lianbo
    Wani, Nissar A.
    Hu, Peng
    Jacob, Samson T.
    Ghoshal, Kalpana
    Payne, Philip R. O.
    Motiwala, Tasneem
    CANCERS, 2020, 12 (10) : 1 - 22
  • [9] Development of Resistance to Sorafenib®, a Multikinase Inhibitor, in Hepatocellular Carcinoma Is Mediated by SIRT
    Garten, Antje
    Grohmann, Theresa
    Barnikol-Oettler, Anja
    Kluckova, Katharina
    Lavery, Gareth
    Kiess, Wieland
    Penke, Melanie
    HORMONE RESEARCH IN PAEDIATRICS, 2018, 90 : 329 - 329
  • [10] HBx Modulates Drug Resistance of Sorafenib-Resistant Hepatocellular Carcinoma Cells
    Liu, Yaping
    Liu, Xu
    Luo, Miaosha
    Li, Yarui
    Li, Hongxia
    DISCOVERY MEDICINE, 2023, 35 (179) : 1035 - 1042
12345